Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.
Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.
The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.
Patients with atrial fibrillation who have had cancer are less likely to see a cardiologist and less likely to fill anticoagulant prescriptions.
Novel Study Shows Efficacy of Anticoagulant Treatment in Very Elderly with Nonvalvular Atrial Fibrillation
A new study fills in information gaps on NOAC use in patients age 80 and over.
ISMP reports that some patients have inadvertently taken double doses of rivaroxaban in dosing mixups.
A large observational study Sweden found that use of anticoagulants by patients with atrial fibrillation reduced the risk of dementia.
A study found that treating patients with rivaroxaban for 45 days after hospital discharge reducedthe rate of nonfatal blood clots, but had no effect on fatal blood clots.
A massive retrospective study compared several non-vitamin K antagonist oral anticoagulants (NOACs) to warfarin.